Berberine Encyclopedia — Scientific Background

What Is Berberine Hydrochloride?

Berberine hydrochloride (CAS 633-65-8) is the hydrochloride salt form of berberine, a naturally occurring benzylisoquinoline alkaloid found in the stems, roots, and rhizomes of various medicinal plants, including Berberis aristata, B. darwinii, B. petiolaris, B. vulgaris, and Coptis chinensis. It is a plant-derived quaternary isoquinoline alkaloid with a low water solubility and can be used in the treatment of various conditions.

Botanical Source

Berberine is extracted from the roots and rhizomes of Coptis chinensis (Chinese goldthread) and various Berberis species. It is a representative protoberberine isoquinoline alkaloid generally existing in the form of hydrochloride, one of the most important natural medicines that can be extracted from plants including Coptis sp. or Berberis sp.. In traditional Chinese and Ayurvedic medicine, berberine has been widely used for its antibacterial, anti-inflammatory, and anti-parasitic effects.

Mechanisms of Action

AMPK Activation — The Central Metabolic Pathway

Berberine‘s primary mechanism of action involves activation of AMP-activated protein kinase (AMPK), a key enzyme in cellular energy regulation. Berberine only weakly stimulates the phosphorylation of Akt/PKB, a key molecule in the insulin signaling pathway, but strongly promotes the phosphorylation of AMPK and p38 MAPK. These results suggest that berberine circumvents insulin signaling pathways and stimulates glucose uptake through the AMP-AMPK-p38 MAPK pathway. Mechanistic studies reveal that berberine decreases mitochondrial membrane potential and intracellular ATP levels and induces potent AMPK activation, as shown by phosphorylation of the AMPK α subunit at Thr-172 and acetyl-CoA carboxylase (ACC) at Ser79.

Glucose and Lipid Metabolism

Berberine improves glucose and lipid metabolism in hepatocytes through AMPKα1 activation. It increases p-AMPKα1, p-AMPKα, and AMPK activity, and stimulates glucose consumption. Berberine influences metabolism, body fat composition, and appetite by activating AMPK.

Gut Microbiome Modulation

Berberine modulates the gut microbiome composition and has been investigated for its role in metabolic crossover effects. Lower doses (300 mg daily) show minimal microbiota effects in research, while standard clinical doses (1,500 mg/day) demonstrate significant microbiome modulation.

Anti-Inflammatory and Antioxidant Effects

Berberine exhibits anti-inflammatory effects through regulating Energy Metabolism of macrophages via the AMPK/HIF-1α pathway. It suppresses glycolysis of LPS-induced M1 macrophages in an AMPK-dependent manner, up-regulating the expression of phosphorylated AMPK and down-regulating hypoxia inducible factor 1α (HIF-1α).

Neuroprotective Effects

Berberine has demonstrated neuroprotective properties, with surface-modified liposomal formulations being investigated for brain targeting in Alzheimer’s therapy.

The Bioavailability Challenge

Despite its broad pharmacological potential, berberine presents significant formulation challenges. The compound has a low water solubility and can be used in the treatment of various conditions, but its therapeutic use has been compromised because of its hydrophobic characteristics, in addition to its low stability and poor bioavailability. The very low oral bioavailability of berberine (below 1%) makes the pharmacological effects hardly available and gives a serious limitation to its clinical utilization.

This has driven the development of advanced delivery systems, including liposomal encapsulation, to enhance berberine bioavailability and therapeutic efficacy.

Liposomal Berberine

Liposomal encapsulation of berberine provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the berberine molecule, forming a shield that protects it from gastric acid degradation and enzymatic metabolism. This delivery system:

• Protects berberine from gastric acid degradation and premature metabolism

• Enhances intestinal absorption through lipid-mediated pathways

• Provides sustained release with prolonged circulation time

• Improves cellular uptake through membrane fusion

Conventional liposomes have low physical and chemical stability due to delicate liposomal membranes, peroxidation, and rapid clearance from the bloodstream. Surface modification of liposomes could be a solution, and creating a liposome with plant-based fibers as surface material provides enhanced stability, aqueous solubility, and protection against degradation. The Fiber Interlaced Liposome™ (FIL) technology has been specifically developed as a vehicle for enhanced bioavailability of berberine, demonstrating a 3.37-fold higher relative oral bioavailability compared to unformulated berberine in animal studies.

Clinical Evidence

Human Pharmacokinetics

A randomized, double-blind, crossover pilot study in six healthy males (age 37.8 ± 3.3 years; weight 74.6 ± 2.9 kg) ingested a single 400 mg dose of berberine, either as unformulated or liposomal berberine. Venous blood samples were collected at multiple time points over 24 hours. Liposomal berberine produced significantly higher pharmacokinetic responses, including a 70.1% increase in Cmax (p = 0.03) and a 42.8% increase in AUC₀–₂₄ (p = 0.03). No significant differences were observed between conditions in 24-hour changes in metabolic or safety markers, confirming that liposomal delivery substantially enhances berberine absorption without negatively affecting metabolic or safety parameters.

Animal Pharmacokinetics

An in vivo bioavailability study using male Wistar rats demonstrated that the FIL-BBR formulation achieved a 3.37-fold higher relative oral bioavailability compared to unformulated berberine. The AUC₀–ₜ for BBR in FIL-BBR was 1.38 ng·h/mL, significantly greater than the unformulated BBR (0.41 ng·h/mL), and the Cmax for BBR in FIL-BBR (50.98 ng/mL) was far greater than unformulated BBR (15.54 ng/mL).

Solid Proliposome Formulation

A separate study using solid berberine proliposomes prepared using solution enhanced dispersion by supercritical CO₂ (SEDS) achieved a high entrapment efficacy of 90.3% ± 4.9% and uniform liposomes around 80 nm. The oral bioavailability for ber-PL was 22.47 times greater than raw berberine, and the mean residence time of berberine in plasma was extended from 6.82 ± 2.99 to 10.83 ± 2.01 hours.

Safety and Regulatory

Berberine hydrochloride is generally well tolerated at commonly used doses. Common dosages include 500 mg of berberine three times per day and before meals. Studies have shown that berberine is safe in doses up to 1,500 mg per day. High doses may cause gastrointestinal discomfort in some individuals, including cramping, diarrhea, and constipation. Liposomal encapsulation helps reduce these side effects through sustained release and improved absorption.

Berberine is widely commercialized as a dietary supplement ingredient. It is a natural medicine that can be extracted from plants including Coptis sp. or Berberis sp.. Regulatory status varies by region, and formulators should verify local requirements prior to market entry. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

139$/KG

119$/KG